Q-omics provides the consensus-scored RNF166 profile across patient tissues and cancer cell-line models. RNF166 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNF166 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, RNF166 RNA expression shows 18,150 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where RNF166 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF166 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF166 survival associations across molecular data types. RNF166 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF166 RNA expression–survival associations across cancer types. High RNF166 expression shows unfavorable associations in KIRC, LGG and ACC, but favorable associations in SKCM, HNSC and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNF166 RNA expression.
This table summarizes RNF166 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RNF166. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF166 shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, KIRP, HNSC and COAD. The KIRC box plot shows higher RNF166 RNA expression in tumor versus normal tissue (log2 FC = +1.023, t-test p < 0.001).
This table shows molecular features associated with RNF166 in patient tissues and cancer cell lines. In patient samples, RNF166 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF166 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
